Microbial Contributions to Arsenic Transformation in the Gut
微生物对肠道中砷转化的贡献
基本信息
- 批准号:10558768
- 负责人:
- 金额:$ 28.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAddressAffectAgeAntidiabetic DrugsArsenicArsenicalsArsenitesCardiovascular DiseasesChronicCollaborationsCommunitiesDiabetes MellitusDrug Metabolic DetoxicationEconomicsEcosystemFermentationFutureGenesGeneticGerm-FreeHealthHealth HazardsHumanIn VitroIngestionKnowledgeMalignant NeoplasmsMediatingMetabolic BiotransformationMetabolic PathwayMetabolismMetalsMethylationMicrobial TaxonomyMolecular AnalysisMusOralOral IngestionOrthologous GeneOutcomePopulationProbioticsPropertyRiskRisk AssessmentSamplingShotgunsSoilSymptomsTailTestingToxic effectcolon microbiotacytotoxicdesigndiabeticdietaryexperienceexposure routegerm free conditiongut microbiomegut microbiotain vivometabolic profilemetagenomemicrobialmicrobial communitymicrobiomemicrobiotamultidisciplinarypreventrRNA Genesresistance generesponsesexsodium arsenitesynthetic constructwastingwestern diet
项目摘要
ABSTRACT (Project 3: Pawel Kiela, Paul Carini, and Albert Barberán)
Legacy mine tailings that remain after extraction of economic metals are frequently enriched with co-occurring
contaminants such as arsenic (As) that pose serious health hazards to neighboring communities and
ecosystems. As-ingestion has been associated with diabetes, numerous cancers, and cardiovascular
disorders. The mode of action for As toxicity is not clear; however, the degree of toxicity is associated with the
valence and the methylation state of As metabolites (e.g. trivalent As species, iAsIII, MMAIII, and DMAIII ,are two
times more cytotoxic than iAsV; methylated pentavalent arsenicals are 10-fold less cytotoxic than AsV). The gut
microbiome is a primary point of contact for As in the host because oral ingestion is the principal exposure
route. In addition, in vitro studies have demonstrated the capacity of human colon microbiota to biotransform
iAs to both more and less toxic forms. Thus, accurate As risk assessment requires understanding of
presystemic contributions by the gut microbiome to the bioaccessibility and speciation of the host As-load. The
overall objectives of this proposal are to 1) contextualize the composition of the mouse gut
microbiome with its functional capacity to metabolize As and to 2) evaluate the capacity of defined As-
transforming microbial communities to affect in vivo diabetic outcomes following As exposure. The
multidisciplinary team will employ a unique approach to identify specific associations between the composition
of the gut microbiome, its genetic and functional capacity to sequester and/or transform As, and its capacity to
either exacerbate or mitigate host diabetic outcomes in response to As exposure. Routine microbial taxonomic
(16S rRNA gene amplicon profiling) and functional gene (shotgun metagenome) analyses will identify the
impact of host sex, age and As-exposure on mouse fecal community composition. This molecular analysis will
be combined with function-based high throughput culture analysis of the same fecal communities to facilitate
the design of 120 distinct synthetic microbial communities (SynComs). The functional capacities of each
SynCom to transform/sequester iAs will be identified and will potentially capture emergent properties of
microbially-mediated As biotransformation that might be missed in studies using isolated phylotypes. The
SynComs will be clustered in functional guilds with differing capacities to increase or decrease the As-load
experienced by the host. These SynComs will be tested in germ-free mice to evaluate the capacity of specific
microbial consortia with distinct As biotransformation capacities to modulate diabetic outcomes of As exposure.
It is hypothesized that microbial communities that reduce As toxicity and associated diabetic outcomes can be
exploited as potential probiotics. This hypothesis will be tested through verification of the ability of positive-
outcome SynComs to colonize a specific pathogen free (SPF) mouse host and prevent or reduce pro-diabetic
effects of iAsIII exposure.
摘要(项目三:Pawel Kiela, Paul Carini和Albert Barberán)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pawel R Kiela其他文献
Pawel R Kiela的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pawel R Kiela', 18)}}的其他基金
Inflammatory Bowel Disease: A Novel Therapeutic Approach
炎症性肠病:一种新的治疗方法
- 批准号:
7341655 - 财政年份:2005
- 资助金额:
$ 28.76万 - 项目类别:
Inflammatory Bowel Disease: A Novel Therapeutic Approach
炎症性肠病:一种新的治疗方法
- 批准号:
7015104 - 财政年份:2005
- 资助金额:
$ 28.76万 - 项目类别:
Inflammatory Bowel Disease: A Novel Therapeutic Approach
炎症性肠病:一种新的治疗方法
- 批准号:
6873496 - 财政年份:2005
- 资助金额:
$ 28.76万 - 项目类别:
Inflammatory Bowel Disease: A Novel Therapeutic Approach
炎症性肠病:一种新的治疗方法
- 批准号:
7564040 - 财政年份:2005
- 资助金额:
$ 28.76万 - 项目类别:
Inflammatory Bowel Disease: A Novel Therapeutic Approach
炎症性肠病:一种新的治疗方法
- 批准号:
7169861 - 财政年份:2005
- 资助金额:
$ 28.76万 - 项目类别:
Microbial Contributions to Arsenic Transformation in the Gut
微生物对肠道中砷转化的贡献
- 批准号:
10337262 - 财政年份:1997
- 资助金额:
$ 28.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 28.76万 - 项目类别:
Research Grant














{{item.name}}会员




